Title:
INDUCIBLE IL-2 AND PD-1/PD-L1 COMBINATION THERAPY
Document Type and Number:
WIPO Patent Application WO/2023/023070
Kind Code:
A3
Abstract:
This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab, an anti-PD-l antibody. The method generally comprises administering to a subject in need thereof an effective amount of an inducible IL-2 prodrug and an anti-PD-l antibody or antigen binding fragment thereof. A preferred anti-PD-l antibody is pembrolizumab. The inducible IL-2 prodrug can be Compound 1, Compound 2, Compound 3, or Compound 4.
More Like This:
| WO/2001/005973 | MACACA CYNOMOLGUS IL18 |
| WO/2020/157129 | OPTIMISATION OF THE SCURFY MODEL FOR IN VIVO TESTING OF INNOVATIVE TREATMENTS OF AUTOIMMUNITY |
| JP4504186 | Treatment with cytokines |
Inventors:
WINSTON WILLIAM (US)
HICKLIN DANIEL (US)
SALMERON-GARCIA JOSE ANDRES (US)
SEIDEL-DUGAN CYNTHIA (US)
BRODKIN HEATHER (US)
ISAACS RANDI (US)
HICKLIN DANIEL (US)
SALMERON-GARCIA JOSE ANDRES (US)
SEIDEL-DUGAN CYNTHIA (US)
BRODKIN HEATHER (US)
ISAACS RANDI (US)
Application Number:
PCT/US2022/040485
Publication Date:
March 23, 2023
Filing Date:
August 16, 2022
Export Citation:
Assignee:
WEREWOLF THERAPEUTICS INC (US)
MSD INT BUSINESS GMBH (CH)
MSD INT BUSINESS GMBH (CH)
International Classes:
A61K38/20; C07K14/55; C07K14/715; C07K16/28; A61P35/00
Domestic Patent References:
| WO2014193898A1 | 2014-12-04 | |||
| WO2021097376A1 | 2021-05-20 |
Foreign References:
| US20170267759A1 | 2017-09-21 |
Attorney, Agent or Firm:
UNDERWOOD, Robert H. (US)
Download PDF:
Previous Patent: CONFIGURATION OF MIXED REALITY OBJECTS IN VIRTUAL REALITY ENVIRONMENTS
Next Patent: VEHICLE CONTROL SYSTEM AND MODULE
Next Patent: VEHICLE CONTROL SYSTEM AND MODULE